Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
This article was originally published in PharmAsia News
Executive Summary
In a transaction that involves no cash moving in either direction, Bristol-Myers Squibb has expanded its territorial rights to an oncology antibody acquired in its 2009 purchase of Medarex, while Ono Pharmaceutical gets co-development and co-commercialization rights to rheumatoid arthritis drug Orencia (abatacept) in Japan
You may also be interested in...
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
Ranked 14th in pharma sales globally, the company isn't even among the top 20 pharmacos in Japan--but it plans on a change in portfolio mix and an emphasis on business development activities to change that profile.